Both mechanistic target of rapamycin (mTOR) pathway and aldosterone are implicated in the development of cardiovascular and renal disease. However, the interaction between aldosterone and the mTOR pathway is unknown. We hypothesized the following: that (i) increased aldosterone will modulate the activity of the mTORC1 and mTORC2 molecular pathways in the heart and kidney; (ii) a physiologic increase in aldosterone will affect these pathways differently than a pathophysiologic one; and (iii) the changes in the mTOR level/activity will differ between the heart and kidney. In both kidney and heart tissues, phosphorylation of mTOR is significantly decreased when aldosterone levels are physiologically increased (by dietary sodium restriction), followed by a decrease in phosphorylated p70S6K1 in cardiac, but not renal, tissue. Sirtuin 1, an epigenetic modulator, is decreased in the heart but increased in the kidney. Conversely, pathophysiologic aldosterone levels (an infusion for 3 weeks) had divergent effects on phosphorylated mTOR and the downstream substrates of mTORC1 and mTORC2 in cardiac and renal tissues. Increased aldosterone levels significantly alter mTOR activity in the heart and kidney. In the kidney, substantial differences were noted if the increase was produced physiologically vs pathophysiologically, suggesting that mTOR activity, in part, may mediate aldosterone-induced renal damage. Thus, modulating mTOR activity may reduce aldosterone-dependent renal damage similar to mineralocorticoid receptor blockade but potentially with less adverse side effects. (Endocrinology 160: 716-728, 2019) C ardiovascular disease (CVD) is the leading cause of death worldwide. An increasing body of data suggests that a major contributor to CVD is primary aldosteronism. Whereas initially described by Conn (1, 2) as an infrequent form of hypertension caused by an adrenal tumor, in the past three decades, the majority of patients with primary aldosteronism does not have a tumor but has bilateral adrenal hyperplasia. However, more recently, it has been documented that an aldosterone-dependent mechanism may also underlie the cardiovascular and/or renal disease in some subjects without hypertension. Indeed, most recently, it has been postulated that upregulated aldosterone for the level of sodium (Na + ) intake may increase the risk of the development of hypertension in individuals who are otherwise healthy (3, 4, 5) . These data suggest that there is a continuum of upregulated aldosterone secretion that may contribute to the pathophysiology of a substantial fraction of individuals with cardiovascular and renal disease (6) . With the use of this definition, a substantial fraction of individuals with CVD, with or without hypertension, likely have an "aldosterone" component to their disease. Excess aldosterone secretion enhances CVD by the promotion of hypertension, endothelial and smooth muscle cell dysfunction, altered nitric oxidesynthesis, vascular damage, left ventricular hypertrophy, renal disease, insulin resistance, heart failure, and inflammation (7) . Intriguingly, the severity of the pathophysiologic state of primary aldosteronism and CVD is substantially modulated by the level of salt intake. These data raise the question as to what may be the secondary mechanisms that could be common to both conditions. Whereas several have been proposed, in general, uncertainty exists (8, 9) . Interestingly, the mechanistic target of rapamycin (mTOR) pathway plays a key role in many of the features common to both excess aldosterone and CVD, namely, the development of cardiac hypertrophy (10), endothelial and smooth muscle cell proliferation, altered nitric oxidesynthesis, inflammation, and altered renal Na + handling (11) (12) (13) . However, the effect of Na + intake and/or aldosterone on mTOR levels or activation is unknown. mTOR is a serine/threonine kinase of 289 kDa that belongs to the phosphoinositide 3-kinase family. mTOR exerts its main cellular functions by forming two distinct complexes: mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2), through assembly with specific adaptor proteins: regulatory-associated protein of mTOR (Raptor) and rapamycin-insensitive companion of mTOR (Rictor), respectively (14) (15) (16) (17) (18) (19) (20) (21) . A simplified diagram of mTOR signaling has been provided in (Fig. 1) . Nutrients, growth factors, cellular energy, and oxygen levels are all upstream regulators of mTORC1, which once activated, is a master promoter of protein synthesis, cell proliferation, ribosomal and mitochondrial biogenesis, autophagy, and metabolism (22) . Much less is known about the mTORC2 pathway; however, it has been shown to be regulated by growth factors and to play a role in cell survival and polarity (23) . mTORC1 activity is increased during the cardiomyocyte hypertrophic response to b-adrenergic stimulation, angiotensin-II, and IGF1; inhibition of mTORC1 inhibits this hypertrophy (24) (25) (26) (27) . There is also evidence that mTORC1 is activated during cardiac hypertrophy induced by physical exercise, transverse aortic constriction, and spontaneous hypertension (28) (29) (30) . In the kidney, ablation of mTORC1 or mTORC2 has led to an understanding of the importance of mTOR signaling during renal injury, glomerular diseases, and polycystic kidney disease (31, 32) . Thus, the goals of this study were threefold. We hypothesized that compared with physiologically reduced aldosterone levels by administration of a high-salt (HS; 1.6% Na + ) diet: (i) increased aldosterone will modulate the activity of the mTORC1 and mTORC2 molecular pathways; (ii) the effect of aldosterone on these pathways will differ substantially when its increased level is appropriate [low-salt (LS) intake; 0.03% Na + ] vs inappropriate (primary aldosteronism model); and (iii) the changes in the mTOR level/activity by these modifications of aldosterone will differ between the heart and kidney.
Methods

Study approval
All procedures were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the guidelines of the Institutional Animal Care and Use Committee at Brigham and Women's Hospital.
HS/LS study
Ten-week-male C57BL/6 mice were purchased from Charles River Laboratories (Wilmington, MA). Mice were housed in the animal facility in a 12-hour light/dark cycle at 22 6 1°C ambient temperature and maintained on ad libitum normal Purina rodent chow (Purina, St. Louis, MO) and tap water. After 3 days of acclimatization, mice were placed on either an HS or LS diet; Purina) for 3 weeks (n = 10 per group). Animals were allowed unlimited access to water.
Primary aldosteronism C57BL/6 mice (11-to 12-week male; Charles River) were randomized into three groups: (i) vehicle, (ii) aldosterone (200 mg/kg/day; Sigma-Aldrich, St. Louis, MO), via Alzet minipumps, and (iii) aldosterone plus 100 mg/kg/day eplerenone via chow (n = 8 per group). All three animal groups were fed a HS diet (Purina) for the entire duration of the 3-week study.
Tissue collection at euthanasia
All mice were euthanized under isoflurane anesthesia (8, 9) , and the hearts and kidneys were immediately excised. Blood was collected via submandibular puncture, and tissues were placed in liquid nitrogen after collection in preparation for mRNA and protein analysis (8, 9) . mRNA expression analysis mRNA was extracted from heart and kidney tissue using the RNeasy mini kit (Qiagen, Germantown, MD). cDNA was Figure 1 . Simplified diagram of aldosterone and salt intake's effect on mTORC1/2 signaling in the heart and kidney.
synthesized from 1.5 mg RNA with the first-strand cDNA synthesis kit (GE Healthcare, Piscataway, NJ). PCR amplification reactions to detect Raptor, Rictor, NAD + -dependent deacetylase Sirtuin-1 (Sirt1), and the housekeeping 18S ribosomal RNA were performed in duplicate using TaqMan geneexpression assays (proprietary primers and probes designed and synthesized by Applied Biosystems, Foster City, CA), using the ABI Prism 7000 sequence detection system (Applied Biosystems). The mRNA expression levels were normalized to 18S ribosomal RNA levels and were determined using DDCT. The data were presented as a fold increase relative to the measurements in HS mice.
Western blot analysis
Protein was extracted by the homogenization of heart and kidney tissues with radioimmunoprecipitation assay lysis buffer (Boston BioProduct, Ashland, MA). Protein extracts (30 mg) were combined with an equal volume of 43 Laemmli loading buffer, boiled for 5 minutes, and run out on 8% SDSpolyacrylamide gels. Proteins were transferred from the gel to a nitrocellulose membrane. Membranes were incubated in 5% nonfat dried milk in Tris-buffered saline-Tween (USB Corp., Cleveland, OH) for 1 hour and then overnight at 4°C with antibody of interest. Rabbit anti-phosphorylated mTOR (33), mTOR (34), phosphorylated p70S6K1 (35), p70S6K1 (36), phosphorylated protein kinase B (Akt) (37), Akt (38), and SIRT1 (39) antibodies were purchased from Cell Signaling Technology (Danvers, MA). Nitrocellulose membranes were washed 3 3 10 minutes in Tris-buffered saline-Tween and then incubated with horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Dallas, TX) for 1 hour, and the reactive proteins were detected using chemiluminescence (BioRad Laboratories, Hercules, CA) and then collected on film and scanned. Each extract was examined three times, and the films were analyzed with optical densitometry. The blots were subsequently reprobed for b-actin (40) (Sigma-Aldrich) for kidney tissue or b-tubulin (41) (Abcam, Cambridge, MA) for heart tissue. The data were first normalized to either housekeeping gene run on that gel to correct for loading, then normalized to HS, and presented as a fold increase relative to the measurements in tissues from HS mice.
Glomerular volume
After excision, kidney and heart tissues were rinsed in PBS and immediately immersed in 10% formalin/4% formaldehyde for 24 hours. Tissues were subsequently placed in 70% ethanol until paraffin embedding, sectioning, and staining. Both heart and kidney tissues were stained with hematoxylin and eosin. Kidney tissue was stained with periodic acid-Schiff. Processing and staining were performed by the Histopathology Rodent Core, Harvard Medical School (Boston, MA). Glomerular volume was measured as previously described (42) .
Statistics
Data are presented as means 6 SEM. In the first study (HS and LS), the Student t test for unpaired data was used to compare groups, except for Raptor and Rictor expression in the heart and kidney; the Fisher exact test was used to compare groups. In the second study (HS, aldosterone, aldosterone + eplerenone], comparisons among the three groups were made with one-way ANOVA, followed by Tukey post hoc test using GraphPad Prism 5 (GraphPad Software, La Jolla, CA). For analysis of AKT in the heart and kidney, the Student t test for unpaired data was used to compare HS-and aldosterone-treated groups. In all studies, differences were considered statistically significant with a twotailed P , 0.05.
Results
LS diet and pathophysiological increases in aldosterone decrease phosphorylated mTOR in the heart mTOR kinase activity is dependent on phosphorylation of Ser-2448 (43); therefore, we assessed the effect of physiologic increases in aldosterone (LS diet) vs reduced aldosterone (HS diet) on the phosphorylation of mTOR Ser-2448. We observed a significant (P = 0.03) decrease in phosphorylation of mTOR in heart tissues from mice on a LS vs an HS diet (Fig. 2a) . We next assessed the impact on phosphorylation of mTOR in a primary aldosteronism model. Cardiac phosphorylation of mTOR was significantly decreased (P , 0.001) when compared with mice on an HS diet alone, similar to what was seen with the LS diet (Fig. 2b) . Eplerenone treatment prevented the aldosteroneinduced decrease in mTOR phosphorylation, indicating that this event is mineralocorticoid receptor (MR) mediated (Fig. 2b) . Pathophysiologic aldosterone also significantly (P , 0.01) reduced mTOR protein levels in these tissues (Fig. 2b) . These results suggest that the reduced myocardial phosphorylation of mTOR likely is a physiologic response to increased aldosterone, but the reduction in mTOR protein levels may be a response to pathophysiologic aldosterone increases (e.g., primary aldosteronism). It should be noted that plasma aldosterone levels in mice from both studies were analyzed, and LS diet animals had approximately the same level of aldosterone as the aldosteroneinfused mice (44) .
LS diet and pathophysiological increases in aldosterone have opposite effects on mTOR phosphorylation in the kidney
We next assessed mTOR phosphorylation in the kidney. LS diet decreased phosphorylation of mTOR (Fig. 2c ) in the kidney, as it did in the heart. However, in contrast to the heart, a pathophysiologic increase in aldosterone increased phosphorylation of mTOR in the kidney (Fig. 2b  and 2d) .
Taken together, these data indicate that pathophysiologic levels of aldosterone are associated with different tissue effects on mTOR.
Aldosterone levels affect expression of Raptor and Rictor
Over the past decade, it has become clear that outcomes of mTOR signaling will differ depending on whether the scaffold proteins Raptor or Rictor bind mTOR, transforming into two distinct signaling complexes: mTORC1 or mTORC2 [reviewed in Laplante and Sabatini (20) ]. Whereas the mechanism(s) by which mTOR preferentially binds Raptor or Rictor remain unclear, it is known that both proteins are essential for mTOR kinase function (45) . Thus, we next assessed which mTOR pathway was activated by a LS diet vs pathophysiologic levels of aldosterone by assessing the levels of Raptor and Rictor mRNA. Increases in aldosterone levels decreased Raptor and Rictor in the heart (Fig. 3a and 3b) . In contrast, in renal tissue, a LS diet increased the expression of Raptor but did not change Rictor expression (Fig. 3c) , whereas both were decreased by pathophysiologic levels of aldosterone (Fig. 3d) . Thus, the effect of appropriate vs inappropriate levels of aldosterone on Raptor and Rictor was the same in the heart but not the kidney. It is unclear why Raptor and Rictor decrease in response to aldosterone when phosphorylation of mTOR is increased in response to aldosterone. However, one potential explanation could be that transcription of these proteins is shutting down through an unidentified feedback mechanism to preserve the organ from overactivation of mTOR signaling in response to pathological aldosterone in the kidney. Treatment with eplerenone did not block the effects of aldosterone in either cardiac or renal tissues ( Fig. 3b and 3d) , suggesting that these effects may not be mediated through the MR.
Increases in aldosterone decrease mTORC1 activity in the heart
To determine how specific extrinsic factors may differentially modulate each pathway, we examined downstream substrates of mTORC1 and mTORC2. mTORC1 phosphorylates and activates the ribosomal protein 70S6K1 (S6 kinase) on Thr-389 (46); recent studies have shown that the mTORC1-S6K1 axis can control cell growth/size; however, this pathway still has incompletely defined roles in cellular physiology [reviewed in Magnuson et al. (47) ]. As the mTORC1-S6K1 axis has been shown to play an important role in tissue and organ size, we hypothesized that p70S6K1 may be affected by changes in aldosterone. In the heart, in response to both LS diet and pathophysiologic increases in aldosterone levels, we observed a decrease in phosphorylation (P , 0.05) of p70S6K1 confirming suppression of mTORC1 activity (Fig. 4a and 4b) . These results are consistent with the aldosterone-induced decrease in phosphorylated mTOR (Fig. 2a and 2b ). Eplerenone treatment was not able to block aldosterone's effect on phosphorylated p70S6K1, suggesting that this may be an MR-independent process. In the kidney, neither LS diet nor pathophysiologic levels of aldosterone had significant effects on phosphorylation of p70S6K1 (Fig. 4c and 4d) . Comparisons among the three groups were made with one-way ANOVA, followed by Tukey post hoc test. Aldo, aldosterone.
mTORC2 activity is increased in response to pathophysiologic aldosterone in the kidney
To determine the effect of aldosterone on the mTORC2 pathway, we assessed phosphorylation of AKT. mTORC2 directly phosphorylates AKT on Ser-473, and this facilitates Thr-308 phosphorylation by phosphoinositide-dependent kinase 1, thereby activating AKT function (48) . We observed no significant change in phosphorylation of AKT at Ser-473 in cardiac or renal tissues in response to a LS diet (Fig. 5a and 5c ). In contrast, in both the kidney and heart, pathophysiologic increases in aldosterone levels increased AKT phosphorylation (more so in the kidney; Fig. 5b and 5d) . Eplerenone blocked the increases, suggesting an MRmediated process.
This observation indicated that abnormal increases in mTORC2 signaling may be detrimental in the kidney. Therefore, we assessed the correlation between kidney to body weight ratio and phosphorylation of mTOR in response to pathophysiologic aldosterone. There was a significant correlation between an increasing kidney weight and levels of phosphorylated mTOR (Fig. 6a) . Given the fact that the kidneys of the aldosterone-infused mice had increased glomerular volume compared with the HS diet controls (44), we next wanted to assess if glomerular volume correlated to phosphorylation of mTOR in the kidney as a marker of damage. As anticipated, increased glomerular volume significantly correlated to increases in mTOR phosphorylation in response to pathophysiological aldosterone (Fig. 6b) .
SIRT1 was strongly correlated with mTOR expression in the heart
Recent data from our laboratory (49, 50) and others (51) have shown salt to be an epigenetic regulator. Therefore, we hypothesized that epigenetic factors may be modulating mTOR expression because of our observation that dietary Na + , as well as aldosterone, impacted total mTOR protein, Raptor, and Rictor mRNA in cardiac tissue. We addressed SIRT1 as a potential candidate. SIRT1 regulates specific metabolic processes, which enable the cell to adapt to nutrient perturbations; for this reason, SIRT1 and mTOR are believed to associate with one another during caloric restriction (52) (53) (54) . Sirt1 has also been implicated in cardiovascular function, where it is suggested to play a protective role in the prevention of cardiac hypertrophy (55) . For these reasons, we hypothesized that SIRT1 may modulate mTOR in response to changes in aldosterone levels in cardiac tissue. SIRT1 protein levels significantly decreased in response to both LS diet (P = 0.01) and pathophysiologic (P , 0.001) levels of aldosterone ( Fig. 7a  and 7b) . Furthermore, the levels of SIRT1 and phosphorylated mTOR, as well as SIRT1 and total mTOR, were highly correlated: r = 0.79 and r = 0.59, respectively ( Fig. 7c and 7d). Transcription of Sirt1 was not affected by dietary Na + in the heart (Fig. 8a) . Thus, we believe that SIRT1 is a potential candidate for regulation of the mTOR pathway in response to changes in aldosterone levels, whether physiologic or pathophysiologic. In contrast to the heart, SIRT1 levels increase in the kidney in response to a LS diet (P = 0.02; Fig. 8a and 8b ).
Discussion
A summary of mTORC1/2 signaling in response to a LS diet and pathophysiological aldosterone in the heart and kidney can be found in Table 1 . In the heart, a LS diet and pathophysiological aldosterone reduced all factors assessed in the mTORC1 molecular pathway and potential epigenetic modulator (SIRT1). In the kidney, changes in aldosterone differed from the heart in most cases. Accompanying these molecular effects were also differences in functional effects, such as increases in renal to body weight ratios and glomerular volume.
In the heart, increases in aldosterone had a more profound effect on mTOR by shutting down both its synthesis and its phosphorylation (Fig. 2) . A potential mediator of this effect is SIRT1, which also was substantially decreased by a LS diet and pathophysiologic increases in aldosterone. The high degree of correlations between phosphorylated mTOR and mTOR protein levels and SIRT1 expression supports this possibility. Decreased expression of Raptor and phosphorylated p70S6K1, in response to both a LS diet and pathophysiologic increases in aldosterone (Figs. 3 and 4) , indicate that mTORC1 vs mTORC2 signaling may be more sensitive to changes in aldosterone levels in cardiac tissues. However, it is possible that mTORC2 is acting on substrates yet to be identified in response to aldosterone. Phosphorylation of Ser-473 on AKT has been detected even in the absence of mTORC2 signaling through ablation of Rictor, especially in cardiac tissue (57) (58) (59) . Therefore, in the heart, it is not surprising that phosphorylated mTOR and Rictor levels decreased in response to increased aldosterone levels, and phosphorylation of AKT remained unchanged or increased. This could also explain why there was a decrease in Rictor expression in response to aldosterone in the kidney.
Several clinical and preclinical studies have documented that aldosterone excess can induce cardiac hypertrophy and fibrosis even with equivalent blood pressure levels. Given the well-documented role that mTOR plays in the development of cardiac hypertrophy (10, 23-25, 60), we speculated that the level of mTOR signaling could explain the lack of cardiac hypertrophy and fibrosis with the increased aldosterone levels associated with salt restriction. Indeed, our results confirm this possibility, as the physiologic increased aldosterone levels with salt restriction were associated with a reduction in nearly all components of the mTOR pathways, thereby protecting against mTOR-mediated cardiac hypertrophy. Hence, a reduction in mTOR signaling may be one potential mechanism by which a LS diet exerts beneficial effects in the heart. Support for this concept comes from a preclinical study. It has been shown in the uninephrectomized deoxycorticosterone acetate salt mouse model that rapamycin treatment significantly reduced left ventricular hypertrophy and inhibited cardiac fibrosis in male mice (61) . It is interesting that in our primary aldosteronism model, one would assume that the effect on the mTOR pathways would have been the opposite of what was observed on the LS diet (62) . However, the hearts were not damaged in our primary aldosteronism model, and the mTOR pathways, if anything, were more strikingly suppressed than what we observed on the LS diet. Thus, it would be of interest to assess whether the activity of mTOR's pathways differs from what was observed in this study in a model associated with cardiac damage.
Conversely, in the kidney, pathophysiologic increases in aldosterone vs a LS diet produced substantial differences. Of the two perturbations in the tissues accessed, only the kidney's phosphorylated mTOR's response to pathophysiologic changes in aldosterone were increased. Pathophysiologic aldosterone increased AKT/mTOR signaling in the kidney, and this is consistent with observations cited in the literature (63) . Taken together, these data may indicate that mTORC2 signaling may be more sensitive to pathophysiologic changes in aldosterone levels in renal tissues vs mTORC1 signaling. It has been shown in human embryonic kidney-293 cells that mTORC2 activates the epithelial Na + channel by the phosphorylation of serum/ glucocorticoid-regulated kinase 1 (64) . The authors go on to demonstrate that mTOR regulates kidney tubule ion handling in vivo and suggest that mTORC2 regulates Na + homeostasis through serum/glucocorticoid-regulated kinase 1-dependent modulation of epithelial Na + channel activity in the kidney (12) . The involvement of mTORC2 with Na + absorption could explain the difference in response to aldosterone between the heart and the kidney. However, the role that mTORC1 plays in response to pathophysiologic aldosterone in the kidney requires further investigation, as in mice, podocyte-specific embryonic knockout of Raptor resulted in albuminuria and development of glomerulosclerosis (31, 65) .
It is interesting that SIRT1 also is modulated by both dietary Na + and pathophysiologic increases in aldosterone (Figs. 7 and 8), and their effect in the kidney and heart differs. In the heart, aldosterone increases produce reduced SIRT1 levels. In the kidney, SIRT1 levels are increased by a LS diet. Given the observation that cardiac SIRT1 and mTOR levels highly correlated in our study (Fig. 7) , it is reasonable to speculate that changes in SIRT1 levels may be one potential mechanism for how aldosterone modulates mTOR signaling in the heart. The relationship between SIRT1 and mTOR, in response to physiologic aldosterone increases, may be analogous to their interaction during caloric restriction. Caloric restriction triggers downregulation of mTORC1 signaling and upregulation of SIRT1 activity, and this is associated with health benefits and longevity (56, 66, 67) . Conversely, SIRT1 has also been shown to deacetylate the C-terminus of S6K1, which relieves inhibition of phosphorylation by mTORC1 in adult gut stem cells (68). The observations that caloric restriction may influence SIRT1 and mTOR differently, depending on tissue type, are consistent with our results comparing the heart and the kidney. It has been hypothesized that overexpression of SIRT1 is protective in various models of renal injury (69) (70) (71) (72) ; therefore, it is reasonable to suspect that increases in SIRT1 and simultaneous decreases in phosphorylation of mTOR in the kidney may be mechanisms by which a LS diet exerts beneficial effects in the presence of high aldosterone levels. Likewise, the abnormal increases in mTORC2 signaling with pathophysiologic aldosterone levels may be detrimental in the kidney, given the fact that the kidneys of the aldosterone-infused mice had increased glomerular volume compared with the HS diet controls (Fig. 6) .
Conditions that expand volume, either by disease or salt intake, without a concomitant, appropriate suppression of aldosterone, increase CVD severity (73) . The mechanisms mediating these effects are unclear. The current study suggests that one potential candidate is mTOR. Dysregulated mTORC1 has long been associated with hypertrophy and inflammation [reviewed in Saxton and Sabatini (11)]. The association between mTOR signaling and physiologic vs pathophysiologic levels of aldosterone supports the hypothesis that altered mTOR signaling mediates these adverse effects. In support of this conclusion are results of a recent animal study, where inhibition of mTORC1 in Dahl salt-sensitive rats attenuates salt-induced hypertension and kidney injury by the reduction of the renal infiltration of T lymphocytes and cell proliferation (74) . Furthermore, there have been studies reported in humans that patients with primary aldosteronism show overactivated mTOR signaling in their adrenals-a disease associated with high blood pressure and CVD (75) . Aldosterone is increasingly being implicated as a cardiovascular risk factor, beyond individuals with primary aldosteronism (e.g., congestive heart failure, renal insufficiency, resistance hypertension, and obesity). Treatment with MR antagonists has been shown or advocated to be effective in treating these conditions. However, as many of these subjects have compromised renal function, there is an increased risk of hyperkalemia. The determination of a mechanistic pathway that does not block the MR in the kidney but inhibits the adverse cardiovascular and renal consequences of CVD is highly desirable. These results suggest that appropriate manipulation of mTOR pathways may be such a mechanism.
One limitation of this study is that we did not uninephrectomize our mice; therefore, our model of aldosterone infusion is not as severe as many cited in the literature. It is unknown how the effect on the mTOR signaling pathways would differ in a model of more severe cardiac damage. Second, only some responses in these experiments were reversed by eplerenone, thereby raising the question as to whether the responses were aldosterone/MR mediated. Plasma renin was significantly increased with the dose of eplerenone chosen (44) . Therefore, we only experimented with one dose of eplerenone (1); it could be that a different dose is required to reverse the effects of aldosterone on different components of mTOR pathways (2) . Other possibilities are that aldosterone is working through a different receptor or that this is a salt effect not mediated by the MR (3). Aldosterone and MR interaction has been shown to be different in specific tissues; this could be why only sometimes eplerenone has an effect.
In conclusion, we documented that the evolutionarily conserved mTOR pathway is sensitive to the level of aldosterone, both induced by physiologic and pathophysiologic increases. The responses in the heart to physiologic changes in aldosterone appear to be protective (reduction in activity). The responses in the kidney to pathophysiologic changes in aldosterone may, in part, mediate the observed adverse effects. A proximate mediator of these effects is a change in SIRT1 expression, as in the heart, its levels were highly correlated with phosphorylated mTOR/mTOR levels. Of interest, changes in SIRT1 levels also have been reported to correlate with changes in calorie intake, another cardiovascular risk factor. Finally, these results raise the intriguing possibility that modulation of the mTOR pathways may be a way to treat aldosterone-mediated damage without the risk of the hyperkalemia associated with MR blockade by reducing aldosterone-associated kidney damage.
